Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment

Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment

Bibliographic Details
Main Authors:	Perl, Shira, Cook, William, Wei, Cheryl, Iqbal, Nayyar, Hirshberg, Boaz
Format:	Online
Language:	English
Published:	Springer Healthcare 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014790/

Similar Items

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
by: Iqbal, Nayyar, et al.
Published: (2014)

Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
by: Pia S. Pollack, et al.
Published: (2017-09-01)

Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥65 years) with type 2 diabetes
by: Iqbal, Nayyar, et al.
Published: (2014)

Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety
by: Jain, Rajeev
Published: (2015)

Efficacy and Safety of Saxagliptin as Add-On Therapy in Type 2 Diabetes
by: Neumiller, Joshua J.
Published: (2014)

The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
by: DeFronzo, Ralph A., et al.
Published: (2009)

Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease
by: Toth, Peter P
Published: (2014)

Efficacy of Saxagliptin versus Mitiglinid in patients with type 2 diabetes and end-stage renal disease
by: Yukinao Sakai, et al.
Published: (2017-04-01)

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
by: Cobble, Michael E, et al.
Published: (2012)

Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina
by: Elgart, Jorge F, et al.
Published: (2013)

Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults
by: Minze, Molly G., et al.
Published: (2013)

Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes
by: Ott, Christian, et al.
Published: (2014)

Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination
by: Panagoulias, George S, et al.
Published: (2014)

Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients
by: Konya, Hiroyuki, et al.
Published: (2014)

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial
by: Frederich, Robert, et al.
Published: (2012)

Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents
by: Li, Chun-Jun, et al.
Published: (2014)

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus
by: Karyekar, Chetan S, et al.
Published: (2013)

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus Patients with Moderate to Severe Renal Impairment: A Systematic Review and Meta-Analysis
by: Cheng, Dongsheng, et al.
Published: (2014)

Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency
by: Arjona Ferreira, Juan Camilo, et al.
Published: (2013)

Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs
by: Saine, M Elle, et al.
Published: (2015)

Comparison of charges and resource use associated with saxagliptin and sitagliptin
by: Vaidya, Varun, et al.
Published: (2016)

Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
by: Derosa, Giuseppe, et al.
Published: (2011)

Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus
by: Dave, Darshan J.
Published: (2011)

Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
by: Shubrook, Jay, et al.
Published: (2011)

Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
by: Messori, Andrea, et al.
Published: (2014)

Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
by: Tatosian, Daniel A., et al.
Published: (2013)

The dipeptidyl peptidase-4 inhibitor Saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients
by: Poncina, Nicol, et al.
Published: (2014)

Comparison of adherence and persistence among adults with type 2 diabetes mellitus initiating saxagliptin or linagliptin
by: Farr, Amanda M, et al.
Published: (2016)

Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China
by: Gu, Shuyan, et al.
Published: (2016)

The burden of type 2 diabetes: strategies to prevent or delay onset
by: Iqbal, Nayyar
Published: (2007)

Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs
by: Hirshberg, Boaz, et al.
Published: (2011)

Cardiovascular Outcome Studies With Novel Antidiabetes Agents: Scientific and Operational Considerations
by: Hirshberg, Boaz, et al.
Published: (2013)

A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy
by: White, Judith L, et al.
Published: (2014)

Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment
by: Schweizer, Anja, et al.
Published: (2013)

Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin
by: Gallwitz, Baptist
Published: (2015)

Pharmacokinetic and Pharmacodynamic Profiles of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment
by: Inagaki, Nobuya, et al.
Published: (2014)

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment
by: Groop, P-H, et al.
Published: (2014)

Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome
by: Birnbaum, Yochai, et al.
Published: (2016)

Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures
by: Neutel, Joel M., et al.
Published: (2013)

Efficacy and Safety of Intacs SK in Moderate to Severe Keratoconus
by: Kotb, Ahmed M. El-Moatassem, et al.
Published: (2013)